



Prescient Scientific Advisory Board Enhanced by Two International CAR-T and Bioengineering Experts

MELBOURNE Australia, 19 November 2021 – Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, today announced the appointment of physician-scientist, Dr Marco Davila of the Moffitt Cancer Center (Moffitt) and bioengineering expert Professor Andrew Tsourkas of the University of Pennsylvania (Penn) to its Scientific Advisory Board (SAB). Dr Davila and Professor Tsourkas bring deep, complementary expertise to Prescient and join a highly credentialed SAB also comprising CAR-T expert Professor Phil Darcy; hematologist and CAR-T researcher Professor H. Miles Prince AM; and brain cancer specialist and cell therapy researcher Professor Don O'Rourke.

Dr. Marco Davila

Dr. Marco Davila is a medical oncologist in the Department of Blood and Marrow Transplantation at the Moffitt Cancer Center, one of the largest comprehensive cancer centres in the US, where he treats patients with hematologic malignancies by using cell therapies. His research involves the pre-clinical development and clinical translation of gene-engineered cell therapies, including CAR-T therapies, for patients with hematologic and solid tumour malignancies.

Dr. Davila is highly experienced in the clinical development of CAR-T and is regarded as a leading figure in the field, often addressing global conferences on the subject.

His research has been acknowledged with grants and/or awards from the American Society of Hematology, Damon Runyon Cancer Research Foundation, American Society of Clinical Oncology, and American Society for Clinical Investigation.

He obtained his MD and PhD degrees at the Duke University School of Medicine and trained in medicine and medical oncology at NY Presbyterian Weill-Cornell and the Memorial Sloan Kettering Cancer Center, respectively.

Dr Davila said, "From my clinical experience with CAR-T therapies, as well as their pre-clinical development, I have seen both the early success of this revolutionary therapy in B cell malignancies, and also the challenges in translating it to other cancers. I am excited by the capabilities of OmniCAR to overcome many of these obstacles and bring gene-engineered cell therapies to many more patients. I am delighted to be appointed to Prescient's SAB to help guide the development of OmniCAR."



Professor Andrew Tsourkas

Professor Tsourkas is a Professor of Bioengineering in the School of Engineering and Applied Sciences at Penn; and Co-Director for the Center for Targeted Therapeutic and Translational Nanomedicine. Professor Tsourkas is a co-inventor of the patents developed at Penn and licensed by Prescient to form OmniCAR.

Bioengineering involves designing and constructing biological components to create commercially valuable products. Professor Tsourkas' particular expertise in the conjugation of proteins is especially relevant to the development of OmniCAR's binders, which involves incorporating SpyTag into antibodies and other antigen-binding molecules.

Professor Tsourkas studied at Cornell University and John Hopkins University before attaining his PhD from the Georgia Tech and Emory University joint Biomedical Engineering program and conducting post-doctoral studies at Harvard Medical School. He has been highly decorated with numerous awards and honours in medical and biological engineering and has published over 100 articles on the topic.

Professor Tsourkas said, "It has been wonderful to see the rapid progress of development of OmniCAR since Prescient licensed the underlying patent from Penn last year. The rapid, covalent nature of OmniCAR's binding confers many unique capabilities and advantages over conventional CAR-T approaches. I look forward to assisting Prescient in the development of OmniCAR and its associated binders to address a variety of different cancers."

On the appointment of both Dr Davila and Professor Tsourkas, Prescient Managing Director and CEO Steven Yatomi-Clarke said, " Dr Davila and Professor Tsourkas bring unsurpassed expertise in the development of CAR-T therapies and in the protein engineering of binders.

We warmly welcome them to Prescient's SAB, which comprises an enviable list of renowned multi-disciplinary experts who bring complementary insights that are necessary to develop an innovative platform like OmniCAR. This diverse expertise is invaluable in guiding OmniCAR through a rapidly evolving cell therapy landscape to create effective therapies for patients that are currently not possible."

- Ends -

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.



About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

Cell Therapy Enhancements: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries:
Sophie Bradley – Reach Markets
+61 450 423 331
ir@reachmarkets.com.au

Media enquiries:
Andrew Geddes – CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website : [Supplemental COVID-19 Risk Factors](#)